Inhibikase Therapeutics (IKT) Profit After Tax Growth (1y) (2021 - 2026)
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Profit After Tax Growth (1y) (2021 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -8.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 94.83% |
| 10 | Inhibikase Therapeutics | 435.56 Mn | 276.54 Mn | - | -97.58% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -97.58% |
| Mar 31, 2026 | -19.75% |
| Dec 31, 2025 | -4.96% |
| Sep 30, 2025 | -106.48% |
| Jun 30, 2025 | -99.93% |
| Mar 31, 2025 | -194.19% |
| Dec 31, 2024 | -190.40% |
| Sep 30, 2024 | -25.74% |
| Jun 30, 2024 | 14.16% |
| Mar 31, 2024 | -3.84% |
| Dec 31, 2023 | 2.36% |
| Sep 30, 2023 | -2.24% |
| Jun 30, 2023 | -24.53% |
| Mar 31, 2023 | 3.51% |
| Dec 31, 2022 | 15.13% |
| Sep 30, 2022 | -0.52% |
| Jun 30, 2022 | -76.01% |
| Mar 31, 2022 | -75.98% |
| Dec 31, 2021 | -317.36% |
| Sep 30, 2021 | -566.75% |